霉酚酸酯治疗小儿频复发肾病综合征的疗效观察

摘要

Objective To investigate the efficacy and adverse effect of mycophenolate mofetil (MMF) in the treatment of frequently relapsing nephrotic syndrome in children. Methods The study population consisted of 37 children (24 simple nephrotic syndrome and 13 nephritis-type syndrome) suffering from frequently relapsing nefor 3 ～6 months. Results Out of 24 patients suffered from simple nephrotic syndrome, 17 patients (70.8%) with complete relief, 4 patients ( 16.7% ) with partial relief and 3 patients ( 12.5% ) with non-relief, whereas out of 13 patients suffered from nephritis-type syndrome 6 patients (46.2%) with complete relief, 3 patients (23.1%) with partial relief and 4 patients ( 30.7% ) with non-relief. Eight patients with Minimal Change Disease ( MCD )achieved complete relief. Of 23 patients with Mesangial Proliferative Glomerulonephritis (MsPGN) or Membranoproliferative Glomerulonephritis (MPGN), complete relief was observed in 17 patients (73.9%), partial relief in 4 patients ( 17.4% ) and non-relief in 2 patients. Conclusion These results suggest that MMF has better efficacy against simple renal disease than against nephritis-type syndrome, and MMF may be more suitable for the treatment of frequently relapsing nephrotic syndrome characterized by proliferative lesions.%目的:观察霉酚酸酯(MMF)治疗小儿频复发肾病综合征的疗效和毒副作用.方法:37例频复发肾病综合征患儿(24例单纯型肾病综合征和13例肾炎型肾病综合征),每日口服MMF(20～30 mg/kg),泼尼松(1 mg/kg),疗程3～6个月.结果:37例肾病患儿中,24例单纯型肾病经MMF治疗后完全缓解17例(70.8%),部分缓解4例(16.7%),未缓解3例(12.5%);而肾炎型肾病13例经MMF治疗后完全缓解6例(46.2%),部分缓解3例(23.1%),未缓解4例(30.7%).8例微小病变(MCD)经MMF治疗后均完全缓解;以增生为主要病变的系膜增生性肾小球肾炎(MsPGN)和膜增生性肾小球肾炎(MPGN)共23例,MMF治疗后完全缓解17例(73.9%),部分缓解4例(17.4%),未缓解2例(8.7%).结论:MMF治疗单纯型肾病综合征频复发病例的效果明显优于肾炎型肾病综合征频复发病例;且对于以增生性病变为主要病理改变的频复发肾病疗效更佳.